127 related articles for article (PubMed ID: 31332772)
1. Acneiform eruption during therapy with aflibercept for metastatic colorectal carcinoma.
Martínez-Doménech A; García-Legaz Martínez M; Magdaleno-Tapial J; Valenzuela-Oñate C; Pérez-Pastor G; Alegre-de Miquel V; Pérez-Ferriols A
Australas J Dermatol; 2020 Feb; 61(1):e107-e108. PubMed ID: 31332772
[No Abstract] [Full Text] [Related]
2. [Acneiform eruptions induced by cetuximab].
Walon L; Gilbeau C; Lachapelle JM
Ann Dermatol Venereol; 2003 Apr; 130(4):443-6. PubMed ID: 12843857
[TBL] [Abstract][Full Text] [Related]
3. Ulcerations on abdominal wound scar associated with aflibercept therapy.
Rivas-Tolosa N; Calomarde L; Bancalari B; Guillén C; Sanmartín O
J Dermatol; 2016 Sep; 43(9):1095-6. PubMed ID: 26970060
[No Abstract] [Full Text] [Related]
4. Severe acneiform eruption induced by cetuximab (Erbitux).
Lee JE; Lee SJ; Lee HJ; Lee JH; Lee KH
Yonsei Med J; 2008 Oct; 49(5):851-2. PubMed ID: 18972607
[TBL] [Abstract][Full Text] [Related]
5. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
Ruff P; Van Cutsem E; Lakomy R; Prausova J; van Hazel GA; Moiseyenko VM; Soussan-Lazard K; Dochy E; Magherini E; Macarulla T; Papamichael D
J Geriatr Oncol; 2018 Jan; 9(1):32-39. PubMed ID: 28807738
[TBL] [Abstract][Full Text] [Related]
6. Acneiform eruption in a patient receiving bevacizumab for glioblastoma multiforme.
Keenan BP; Abuav R
Arch Dermatol; 2010 May; 146(5):577. PubMed ID: 20479324
[No Abstract] [Full Text] [Related]
7. Aflibercept: A Review in Metastatic Colorectal Cancer.
Syed YY; McKeage K
Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913
[TBL] [Abstract][Full Text] [Related]
8. Early small bowel perforation due to aflibercept.
Moussallem T; Lim C; Osseis M; Esposito F; Lahat E; Fuentes L; Salloum C; Azoulay D
Drug Discov Ther; 2017 Nov; 11(5):291-292. PubMed ID: 29021501
[TBL] [Abstract][Full Text] [Related]
9. Aflibercept. Metastatic colorectal cancer: at least as poorly tolerated as bevacizumab.
Prescrire Int; 2014 Sep; 23(152):205. PubMed ID: 25325116
[TBL] [Abstract][Full Text] [Related]
10. Acneiform eruption induced by cetuximab.
Cotena C; Gisondi P; Colato C; Girolomoni G
Acta Dermatovenerol Croat; 2007; 15(4):246-8. PubMed ID: 18093454
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.
Lambrechts D; Thienpont B; Thuillier V; Sagaert X; Moisse M; Peuteman G; Pericay C; Folprecht G; Zalcberg J; Zilocchi C; Margherini E; Chiron M; Van Cutsem E
Br J Cancer; 2015 Sep; 113(7):1027-34. PubMed ID: 26355232
[TBL] [Abstract][Full Text] [Related]
12. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor.
Fernandez-Galar M; España A; López-Picazo JM
Clin Exp Dermatol; 2004 Mar; 29(2):138-40. PubMed ID: 14987267
[TBL] [Abstract][Full Text] [Related]
13. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer.
Jo JC; Hong YS; Kim KP; Lee JL; Kim HJ; Lee MW; Lim SB; Yu CS; Kim JC; Kim JH; Kim TW
Eur J Dermatol; 2013; 23(1):77-82. PubMed ID: 23238388
[TBL] [Abstract][Full Text] [Related]
14. Aflibercept-related sterile inflammation.
Hahn P; Kim JE; Stinnett S; Chung MM; Dugel PU; Flynn HW; Huang SS; Sadda SR; Mahmoud TH;
Ophthalmology; 2013 May; 120(5):1100-101.e1-5. PubMed ID: 23642742
[No Abstract] [Full Text] [Related]
15. Medication-related osteonecrosis of the jaw associated with aflibercept.
Zarringhalam P; Brizman E; Shakib K
Br J Oral Maxillofac Surg; 2017 Apr; 55(3):314-315. PubMed ID: 27923511
[No Abstract] [Full Text] [Related]
16. Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.
Vaccaro M; Guarneri F; Borgia F; Pollicino A; Altavilla G; Cannavò SP
J Dermatolog Treat; 2016; 27(2):148-52. PubMed ID: 26313697
[TBL] [Abstract][Full Text] [Related]
17. [Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid].
Wollenberg A; Moosmann N; Kroth J; Heinemann V; Klein E
Hautarzt; 2007 Jul; 58(7):615-8. PubMed ID: 17146641
[TBL] [Abstract][Full Text] [Related]
18. [Acneiform eruption secondary to cetuximab with pseudomalignant histopathological changes].
Vidal-Olmo I; Bassas-Vila J; Herrera-Acosta E; Umbert-Millet P
Actas Dermosifiliogr; 2008 Mar; 99(2):159-60. PubMed ID: 18346444
[No Abstract] [Full Text] [Related]
19. Complications of therapy and a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab.
Monti M; Mancini LL; Ferrari B; Rahal D; Santoro A
J Clin Oncol; 2003 Dec; 21(24):4651-3. PubMed ID: 14673056
[No Abstract] [Full Text] [Related]
20. How to Manage the Side Effects of New Targets Agents for Metastatic Colorectal Cancer.
Becze E
ONS Connect; 2016 Jan; 31(1):24-5. PubMed ID: 26887105
[No Abstract] [Full Text] [Related]
[Next] [New Search]
